Chemiluminescencross bone gla protein (BGP) for Automatic immunoassay analyzer in Bone Metabolism
【expected usage】
This product is used to quantitatively detect the content of osteocalcin (BGP) in human serum in vitro.
Osteocalcin (Osteocalcin), also known as BoneG-Gla Protein (BGP), is an acidic protein, which is vitamin K-dependent and contains three γ-carboxyglutamic acid side chains , γ-carboxyglutamic acid in BGP is very important for its biological properties, and BGP can be combined with Ca2+ after carboxylation. BGP is one of the most abundant non-collagen bone proteins in bone, and is ubiquitous in all vertebrate bones and teeth. It accounts for about 25% of the total collagen in adult bone. Vitamin K is an indispensable substance for the synthesis of BGP, and its synthesis is regulated by 1,25(OH)2D3. The use of vitamin K antagonists can reduce the content of this protein in bone, but does not affect its proline content, nor does it affect the mechanical strength of bone. Osteocalcin is the most abundant non-collagen protein in bones and is synthesized into the blood by osteoblasts. The half-life in blood is 4~5min, which is the most sensitive and specific indicator reflecting the activity of osteoblasts. Osteocalcin values vary with age and with changes in bone turnover rates. The faster the bone turnover rate, the higher the osteocalcin value, and vice versa.
In primary osteoporosis, postmenopausal osteoporosis is a high conversion type, so osteocalcin is significantly increased; senile osteoporosis is a low conversion type, so osteocalcin is not significantly increased. Therefore, it is possible to identify whether osteoporosis is high-conversion type or low-conversion type according to the changes of osteocalcin. It should be noted that osteocalcin is significantly elevated in hyperparathyroid osteoporosis. , The change of serum BGP concentration is of great significance to the clinical research on the pathogenesis of bone diseases and endocrine and metabolic bone diseases and the study of bone components.
The current clinical and laboratory determination methods for osteocalcin include enzyme-linked immunosorbent assay, colloidal gold method, fluorescence immunoassay, and chemiluminescence method.
| Test item | BGP |
| Specification | 100 Test/Box for CIA series |
| 24 Test/Box for POCT |
| Principle | sandwich method |
| Component | Magnetic Beads |
| Calibrator Low |
| Calibrator High |
| BGP Anti |
| Control 1 |
| Control 2 |
| Accessories Required But Not Provided | Substrate |
| Washing solution |
| Sample material | serum |
| Sample volume | More than 200μL |
| Storage | 2-8℃ |
Serum Osteocalcin (BGP) Introduction:
Osteocalcin is synthesized and secreted by osteoblasts, which is relatively stable and is not affected by bone resorption factors.
Serum osteocalcin can be used to understand the activity state of osteoblasts, especially newly formed osteoblasts.
Osteocalcin values vary with age and with changes in bone turnover rates. The faster the bone turnover rate, the higher the osteocalcin value, and vice versa.
In primary osteoporosis, postmenopausal osteoporosis is a high conversion type, so osteocalcin is significantly increased; senile osteoporosis is a low conversion type, so osteocalcin is not significantly increased. Therefore, it is possible to identify whether osteoporosis is high-conversion type or low-conversion type according to the changes of osteocalcin. It should be noted that osteocalcin is significantly elevated in hyperparathyroid osteoporosis.
Serum osteocalcin (BGP) normal value:
4.8-10.2ug/L.
The clinical significance of serum osteocalcin (BGP):
Elevated: seen in bone synthesis, especially in the early stage of bone synthesis after bone injury, postmenopausal osteoporosis, hyperparathyroidism osteoporosis.
|
|
Chemiluminescencross bone gla protein (BGP) for Automatic immunoassay analyzer in Bone Metabolism Images
|
